pandem
influenza
global
health
threat
outbreak
need
new
countermeasur
rapidli
implement
plasma
therapi
use
experiment
past
year
treat
sever
infecti
diseas
diphtheria
spanish
flu
pandem
sever
acut
respiratori
syndrom
ebola
epidem
west
africa
recent
middl
east
respiratori
syndrom
metaanalysi
eight
nonrandomis
studi
convalesc
blood
product
influenza
pandem
calcul
casefat
rate
among
treat
particip
compar
among
cohort
studi
particip
sever
influenza
demonstr
lower
mortal
treatment
group
receiv
convalesc
plasma
versu
control
group
receiv
standard
care
vs
although
mortal
control
group
higher
expect
compar
sever
despit
encourag
data
randomis
control
trial
immun
plasma
sever
influenza
ever
done
suggest
reason
studi
expens
complex
work
experiment
blood
product
hard
mani
blood
establish
intervent
commercialis
reluct
use
blood
product
due
perceiv
associ
risk
effort
rigor
assess
role
immun
plasma
treatment
sever
influenza
randomis
control
trial
nonpandem
set
particip
respiratori
compromis
due
influenza
randomis
openlabel
multicentr
phase
trial
involv
academ
medic
centr
usa
studi
particip
provid
written
inform
consent
studi
protocol
approv
institut
review
board
studi
site
research
context
evid
studi
search
pubm
octob
studi
immun
plasma
treatment
influenza
respiratori
viral
diseas
metaanalysi
previou
cohort
studi
influenza
pandem
show
casefat
rate
among
particip
treat
plasma
serum
whole
blood
compar
among
control
howev
exclus
detail
intervent
eg
antibodi
titr
structur
outcom
assess
studi
difficult
assess
cohort
studi
convalesc
plasma
treatment
pandem
influenza
result
mortal
treatment
group
versu
control
group
howev
mortal
control
group
studi
higher
expect
rais
concern
bia
patient
select
previou
randomis
studi
identifi
treatment
influenza
convalesc
plasma
ad
valu
studi
knowledg
studi
first
randomis
treatment
studi
investig
use
immun
plasma
treatment
sever
season
influenza
find
show
patient
treat
convalesc
plasma
trend
reach
statist
signific
toward
faster
resolut
respiratori
ill
measur
tachypnoea
hypoxia
well
improv
multipl
secondari
endpoint
clinic
statu
hospit
stay
durat
intens
care
unit
requir
mechan
ventil
safeti
data
show
intervent
well
toler
evid
worsen
influenza
diseas
advers
effect
plasma
administr
implic
avail
evid
evid
studi
show
immun
plasma
might
effect
treatment
treatment
sever
influenza
due
small
number
particip
studi
lack
treatment
blind
find
confirm
randomis
blind
clinic
trial
particip
admit
hospit
influenza
b
viru
infect
diagnos
local
rapid
antigen
pcr
either
hypoxia
room
air
satur
oxygen
tachypnoea
respiratori
rate
greater
breath
per
min
adult
agedefin
threshold
breath
per
min
children
elig
enrol
studi
initi
restrict
onset
ill
within
day
enrol
subsequ
revis
allow
particip
enrol
regardless
onset
time
activ
viral
replic
evidenc
posit
diagnost
test
studi
initi
enrol
particip
influenza
amend
also
includ
influenza
b
particip
exclud
abocompat
plasma
avail
receiv
investig
antivir
previou
week
histori
allerg
reaction
blood
product
medic
condit
could
toler
ml
volum
plasma
infus
clinic
suspicion
caus
acut
ill
primarili
due
condit
activ
influenza
viru
replic
eg
primarili
bacteri
superinfect
per
protocol
nonpregn
adult
enrol
first
year
subsequ
data
safeti
monitor
board
review
interim
data
children
pregnant
women
also
made
elig
enrol
particip
randomli
assign
onlin
randomis
system
ratio
receiv
either
two
unit
abocompat
plasma
volum
rang
mlunit
mlkg
paediatr
equival
studi
day
addit
standard
care
versu
standard
care
alon
standard
care
vari
depend
clinic
need
patient
particip
requir
receiv
neuraminidas
inhibitor
part
treatment
computergener
central
randomis
scheme
use
stratif
age
group
pregnanc
statu
year
year
year
year
year
pregnant
year
pregnant
pregnant
randomis
stratifi
site
measur
diseas
sever
studi
blind
studi
use
unit
human
plasma
met
requir
us
food
drug
administr
fda
licens
fresh
frozen
plasma
prescreen
haemagglutin
inhibit
titr
central
laboratori
unit
requir
haemagglutin
inhibit
titr
least
although
unit
use
particip
influenza
geometr
mean
haemagglutin
inhibit
titr
rang
influenza
b
geometr
mean
haemagglutin
inhibit
titr
begin
studi
plasma
collect
donordirect
programm
screen
particip
high
titr
haemagglutin
inhibit
serial
collect
plasma
individu
cours
studi
plasma
collect
chang
screen
unit
plasma
blood
establish
identifi
unit
high
haemagglutin
inhibit
titr
influenza
influenza
b
allow
larger
volum
plasma
collect
support
treatment
studi
studi
plasma
administ
soon
possibl
later
h
randomis
rate
infus
dictat
institut
practic
two
infus
separ
least
h
assess
immedi
advers
event
first
unit
interv
unit
could
extend
clinic
indic
particip
assess
studi
day
predos
studi
day
nasal
oropharyng
swab
influenza
pcr
collect
day
take
swab
day
previou
data
suggest
patient
shed
viru
day
endotrach
aspir
obtain
possibl
baselin
apach
ii
score
calcul
routin
physiolog
measur
age
previou
health
statu
previous
baselin
prism
iii
score
calcul
physiolog
variabl
previous
overal
object
studi
assess
safeti
efficaci
treatment
antiinfluenza
immun
plasma
addit
standard
care
patient
influenza
primari
efficaci
endpoint
normalis
tachypnoea
hypoxia
defin
normalis
respiratori
rate
breath
per
min
adult
age
defin
threshold
breath
per
min
children
room
air
satur
oxygen
higher
secondari
endpoint
includ
incid
durat
clinic
symptom
fever
time
resolut
symptom
fever
inhospit
day
mortal
durat
hospit
stay
number
admiss
durat
admiss
intens
care
unit
icu
incid
durat
supplement
oxygen
incid
acut
respiratori
distress
syndrom
incid
durat
requir
mechan
ventil
disposit
home
health
care
home
health
care
transfer
longterm
care
facil
hospit
stay
ongo
day
discharg
hospic
care
deceas
last
hospit
discharg
secondari
analysi
includ
subgroup
prespecifi
formal
statist
analysi
plan
except
six
step
ordin
scale
clinic
statu
day
develop
separ
antiinfluenza
intraven
hyperimmun
immunoglobulin
studi
use
posthoc
studi
limit
data
avail
base
sampl
size
calcul
studi
howev
sampl
size
calcul
suffici
detect
decreas
median
time
normalis
respiratori
statu
day
day
power
twosid
signific
level
efficaci
result
shown
primari
efficaci
popul
unless
otherwis
note
primari
efficaci
popul
includ
particip
influenza
infect
confirm
pcr
day
central
laboratori
randomli
assign
treatment
group
analysi
per
intentiontotreat
log
rank
test
cox
proport
hazard
model
use
compar
primari
endpoint
treatment
intentiontotreat
approach
primari
endpoint
particip
die
without
normalis
censor
day
particip
assess
schedul
visit
either
due
previou
loss
followup
incomplet
miss
evalu
consid
normalis
respiratori
statu
visit
advers
event
data
code
medic
dictionari
regulatori
activ
version
shown
treatment
receiv
employe
funder
studi
involv
studi
design
analysi
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
jan
march
total
particip
screen
studi
figur
particip
exclud
eight
posit
test
influenza
two
judg
unabl
toler
ml
volum
two
blood
type
abocompat
plasma
avail
three
exclud
reason
particip
site
enrol
least
one
particip
trial
enrol
stop
march
end
influenza
season
studi
size
within
two
particip
enrol
goal
particip
randomli
assign
particip
exclud
primari
efficaci
popul
initi
sampl
pcr
neg
central
laboratori
test
miss
median
age
patient
randomli
assign
treatment
group
year
rang
year
children
two
pregnant
women
enrol
tabl
particip
underli
medic
condit
hypertens
chronic
obstruct
pulmonari
diseas
common
medic
condit
present
particip
shown
tabl
particip
median
day
influenza
ill
enrol
receiv
antivir
receiv
oseltamivir
one
receiv
oseltamivir
zanamivir
randomis
median
day
iqr
antivir
enrol
particip
receiv
naproxen
six
particip
receiv
azithromycin
baselin
particip
case
report
form
requir
oxygen
icu
mechan
ventil
tabl
adult
median
apach
ii
score
reflect
anticip
wherea
children
median
prism
iii
score
reflect
anticip
particip
randomli
assign
receiv
standard
care
slightli
sever
ill
baselin
compar
assign
plasma
oxygen
requir
patient
vs
patient
mechan
ventil
patient
vs
patient
patient
abnorm
radiograph
particip
multilobar
infiltr
chest
radiograph
proport
similar
group
tabl
patient
pleural
effus
common
standard
care
group
vs
tabl
protocol
mandat
assess
pleural
effus
although
empyema
report
loss
followup
complet
studi
day
higher
particip
receiv
standard
care
ten
vs
four
though
followup
primari
endpoint
day
reach
primari
endpoint
death
similar
vs
particip
randomli
assign
plasma
treatment
group
receiv
full
plan
treatment
four
particip
randomli
assign
receiv
plasma
actual
receiv
plasma
figur
one
paediatr
particip
randomli
assign
standard
care
inadvert
administ
plasma
particip
receiv
plasma
first
unit
plasma
administ
median
h
iqr
randomis
median
h
unit
particip
receiv
antivir
receiv
oseltamivir
monotherapi
one
receiv
zanamivir
one
receiv
oseltamivir
zanamivir
particip
receiv
antibiot
protocol
dictat
antibiot
would
use
particip
randomli
assign
receiv
plasma
document
resolut
tachypnoea
hypoxia
day
compar
control
particip
figur
hr
plasma
standard
care
versu
standard
care
alon
ci
kaplanmei
analysi
caveat
studi
evalu
tachypnoea
hypoxia
day
everi
day
estim
median
time
resolut
tachypnoea
hypoxia
day
lower
quartil
day
among
particip
randomli
assign
receiv
plasma
versu
day
lower
quartil
day
among
particip
randomli
assign
standard
care
group
due
higher
expect
loss
followup
sensit
analysi
done
followup
censor
last
avail
assess
suffici
respiratori
statu
data
six
particip
randomli
assign
receiv
plasma
resolv
tachypnoea
hypoxia
present
screen
time
baselin
receiv
plasma
compar
one
particip
receiv
standard
care
particip
exclud
analysi
particip
primari
efficaci
popul
randomli
assign
receiv
plasma
resolut
tachypnoea
hypoxia
day
compar
control
benefit
primarili
report
particip
enrol
within
day
symptom
treatment
subgroup
interact
figur
particip
randomli
assign
standard
care
slightli
sever
diseas
baselin
assess
influenc
baselin
differ
analysi
done
stratifi
use
oxygen
mechan
ventil
icu
requir
presenc
acut
respiratori
distress
syndrom
stratifi
analys
show
similar
result
primari
analysi
stratifi
log
rank
appendix
particip
randomli
assign
plasma
group
better
disposit
hospit
discharg
tabl
similar
find
note
posthoc
analysi
use
six
step
scale
clinic
statu
day
death
icu
ongo
hospitalis
oxygen
hospit
stay
oxygen
admit
hospit
return
normal
activ
admit
hospit
return
normal
activ
better
outcom
among
particip
randomli
assign
receiv
plasma
primari
efficaci
popul
across
multipl
prespecifi
measur
efficaci
also
observ
though
achiev
statist
signific
tabl
particip
randomli
assign
receiv
plasma
spent
numer
fewer
day
hospit
randomis
median
day
iqr
vs
day
numer
fewer
particip
icu
admiss
vs
numer
fewer
day
mechan
ventil
median
day
iqr
vs
day
contrast
differ
day
supplement
oxygen
randomis
median
day
iqr
vs
day
number
day
icu
randomis
median
day
iqr
vs
day
case
primari
endpoint
benefit
seem
greatest
particip
symptom
within
day
randomis
appendix
without
acut
respiratori
distress
syndrom
baselin
particip
randomli
assign
receiv
plasma
went
develop
acut
respiratori
distress
syndrom
wherea
three
particip
receiv
standard
care
differ
treatment
report
time
resolut
typic
influenza
symptom
resolut
fever
appendix
six
particip
die
studi
one
randomli
assign
receiv
plasma
compar
five
particip
randomli
assign
receiv
standard
care
intentiontotreat
analysi
hr
ci
one
particip
die
receiv
plasma
die
day
plasma
infus
due
septic
shock
death
deem
relat
studi
intervent
analysi
treatment
receiv
restrict
primari
efficaci
popul
gave
similar
result
particip
randomli
assign
receiv
plasma
log
copi
per
ml
lower
nasal
oral
influenza
viral
load
detect
quantit
pcr
baselin
assign
standard
care
alon
nasal
median
copi
per
ml
vs
copi
per
ml
oral
copi
per
ml
vs
copi
per
ml
although
viral
load
particip
endotrach
aspir
vs
copi
per
ml
similar
treatment
group
tabl
signific
differ
time
viru
becom
undetect
nasal
oral
figur
haemagglutin
inhibit
titr
achiev
infus
plasma
determin
separ
particip
preexist
immun
immun
respons
strain
circul
throughout
studi
geometr
mean
haemagglutin
inhibit
titr
studi
particip
baselin
ci
plasma
recipi
versu
ci
control
versu
day
day
versu
day
geometr
mean
haemagglutin
inhibit
titr
similar
ci
vs
similar
result
note
titr
appendix
influenza
b
differ
haemagglutin
inhibit
titr
note
treatment
group
appendix
studi
popul
seriou
advers
event
fewer
plasma
recipi
control
seriou
advers
event
nine
patient
vs
patient
common
seriou
advers
event
acut
respiratori
distress
syndrom
stroke
occur
three
particip
one
plasma
recipi
two
control
tabl
seriou
advers
event
appear
frequent
among
plasma
recipi
common
advers
event
occur
first
day
hyperglycaemia
increas
aspart
aminotransferas
diarrhoea
anaemia
fever
tabl
use
immun
plasma
recommend
primari
therapi
sever
respiratori
infecti
diseas
includ
influenza
sever
acut
respiratori
syndrom
middl
east
respiratori
howev
data
support
recommend
weak
limit
case
report
case
seri
one
case
control
addit
randomis
control
hyperimmun
antiinfluenza
immunoglobulin
show
benefit
mortal
icu
stay
hospit
stay
durat
posthoc
analysi
particip
treat
within
day
symptom
onset
reduc
mortal
none
vs
four
ten
odd
ratio
although
convers
treat
day
increas
mortal
five
five
vs
none
seven
statist
analysi
report
knowledg
randomis
control
trial
first
immun
plasma
treatment
respiratori
viru
diseas
although
studi
abl
conclus
show
efficaci
basi
primari
endpoint
resolut
tachypnoea
hypoxia
compar
standard
care
group
patient
treatment
group
resolut
tachypnoea
hypoxia
signific
improv
report
clinic
statu
day
numer
decreas
mortal
one
patient
vs
five
patient
particip
plasma
group
treat
within
day
symptom
onset
show
faster
normalis
respiratori
statu
compar
patient
treat
greater
day
symptom
onset
although
definit
conclus
requir
studi
base
data
larger
randomis
doubleblind
placebo
control
trial
underway
intervent
seem
safe
numer
fewer
particip
plasma
group
seriou
advers
event
compar
particip
randomis
standard
care
vs
seriou
advers
event
report
seem
larg
relat
underli
influenza
complic
comorbid
condit
due
intervent
although
assess
safeti
difficult
serious
ill
popul
given
high
number
seriou
advers
event
advers
event
particip
receiv
standard
care
abil
discern
subtl
safeti
signal
associ
intervent
ill
popul
challeng
given
morbid
influenza
children
pregnant
women
import
incorpor
popul
studi
although
enrol
suffici
number
children
pregnant
women
make
discret
statement
efficaci
subpopul
shown
feasibl
would
argu
necessari
incorpor
popul
trial
novel
influenza
therapeut
sever
diseas
absenc
measur
antivir
effect
difficult
interpret
need
virolog
efficaci
endpoint
influenza
therapeut
well
date
even
oseltamivir
shown
conclus
efficaci
term
decreas
viral
previou
antiinfluenza
convalesc
plasma
report
differ
rate
decreas
viral
shed
although
cohort
design
high
mortal
control
group
make
direct
comparison
studi
difficult
previou
hyperimmun
antiinfluenza
immunoglobulin
show
virolog
benefit
day
although
previous
note
show
clinic
benefit
primari
analysi
present
fda
consid
virolog
endpoint
alon
suffici
primari
endpoint
given
absens
predict
relationship
reduct
viral
titr
clinic
benefit
well
substanti
variabl
method
quantifi
viral
use
haemagglutin
inhibit
titr
measur
immun
prevent
influenza
well
therefor
increas
haemagglutin
inhibit
titr
immun
plasma
might
anticip
decreas
viral
shed
addit
sever
hundr
unit
plasma
screen
week
support
studi
assay
need
scalabl
high
throughput
reason
plasma
unit
studi
screen
haemagglutin
inhibit
howev
previou
cohort
antiinfluenza
convalesc
plasma
unit
screen
neutralis
antibodi
titr
although
neutralis
antibodi
titr
haemagglutin
inhibit
gener
relat
suffici
data
indic
appropri
method
screen
plasma
unit
addit
possibl
system
administ
antibodi
suffici
permeat
mucos
surfac
affect
viral
replic
studi
numer
differ
geometr
mean
titr
plasma
treatment
group
compar
particip
control
group
first
day
plasma
administr
analysi
pharmacokinet
pharmacodynam
relationship
intervent
howev
present
sever
challeng
administ
plasma
discern
intrins
immun
respons
unlik
small
molecul
baselin
titr
begin
zero
due
preexist
immun
previou
infect
vaccin
well
immun
respons
occur
ill
onset
day
titr
higher
particip
regardless
treatment
due
adapt
immun
respons
remain
elev
baselin
month
given
complex
type
analysi
pharmacokinet
pharmacodynam
relationship
beyond
scope
articl
abl
record
effect
immun
plasma
decreas
symptom
influenza
ill
given
sever
natur
ill
studi
popul
icu
abil
ascertain
symptom
sever
reliabl
way
easili
reproduc
might
inde
question
also
differ
group
number
day
followup
oxygen
supplement
use
despit
suggest
improv
resolut
tachypnoea
hypoxia
plasma
recipi
result
might
conceiv
reflect
practic
intent
omiss
delay
discontinu
supplement
oxygen
despit
resolut
hypoxia
use
ordin
scale
clinic
statu
level
care
done
analysi
avoid
much
variat
report
primari
endpoint
although
origin
develop
use
differ
influenza
therapeut
studi
origin
analysi
plan
use
scale
signific
differ
outcom
treatment
group
day
note
studi
sever
limit
limit
previou
data
effect
size
could
determin
sampl
size
calcul
end
studi
underpow
unblind
design
anoth
limit
studi
potenti
placebo
eg
salin
albumin
debat
protocol
develop
although
even
elabor
blind
scheme
studi
team
unlik
effect
blind
ultim
conclud
incorpor
placebo
await
larger
definit
trial
one
unintend
consequ
decis
unblind
studi
design
observ
loss
followup
seem
somewhat
higher
particip
receiv
standard
care
compar
receiv
plasma
consent
inform
specif
studi
treatment
would
provid
suspect
particip
receiv
standard
care
less
motiv
complet
studi
visit
howev
loss
followup
compromis
abil
ascertain
data
primari
endpoint
baselin
differ
oxygen
depend
proport
patient
use
mechan
ventil
apach
score
suggest
standard
care
group
might
particip
present
sever
diseas
due
associ
age
pregnanc
outcom
influenza
chosen
primari
stratif
categori
randomis
limit
sampl
size
concern
addit
stratif
could
led
incomplet
fill
block
stratif
subsequ
imbal
differ
sever
ill
like
also
account
higher
viral
burden
nasal
oropharyng
swab
baselin
standard
care
group
varieti
reason
studi
type
prove
difficult
execut
despit
engag
establish
investig
infecti
diseas
intens
care
emerg
medicin
academ
medic
centr
enrol
random
assign
particip
took
year
major
challeng
includ
low
incid
influenza
ill
year
studi
scarciti
experi
blood
establish
use
plasma
investig
product
particip
famili
even
treat
physician
also
express
reluct
use
human
blood
product
diseas
influenza
morbid
mortal
often
underappreci
addit
challeng
uniqu
investig
product
includ
move
target
antigen
drift
circul
influenza
subtyp
need
match
evolut
time
contemporan
plasma
compar
short
shelf
life
plasma
unit
necessit
frequent
replenish
expir
unit
although
primari
endpoint
reach
statist
signific
trial
show
improv
outcom
secondari
endpoint
clinic
statu
day
particip
receiv
plasma
compar
standard
care
alon
addit
endpoint
might
suggest
improv
outcom
patient
given
need
better
therapi
influenza
well
need
strategi
place
rapidli
launch
effect
therapeut
countermeasur
diseas
type
critic
import
accur
determin
efficaci
immun
plasma
consider
believ
approach
studi
larger
randomis
trial
note
trial
present
underway
